Analysis and Commentary STEVEN GROSSMAN 12/5/20 Analysis and Commentary STEVEN GROSSMAN 12/5/20 CDRH Update and Future Priorities Read More Analysis and Commentary STEVEN GROSSMAN 11/19/20 Analysis and Commentary STEVEN GROSSMAN 11/19/20 Time to Give Thanks -- Once Again Read More Advocacy at a Glance STEVEN GROSSMAN 11/20/20 Advocacy at a Glance STEVEN GROSSMAN 11/20/20 What Happened in 2020? Insights from DC's Top Election Handicapper Read More Analysis and Commentary STEVEN GROSSMAN 11/12/20 Analysis and Commentary STEVEN GROSSMAN 11/12/20 Where $40 Million Might Go for FY 21 Read More Advocacy at a Glance STEVEN GROSSMAN 11/13/20 Advocacy at a Glance STEVEN GROSSMAN 11/13/20 Progress on Appropriations; How Much Progress is Unclear Read More Analysis and Commentary STEVEN GROSSMAN 11/8/20 Analysis and Commentary STEVEN GROSSMAN 11/8/20 What Happens in the Next Few Months? Read More Advocacy at a Glance STEVEN GROSSMAN 11/8/20 Advocacy at a Glance STEVEN GROSSMAN 11/8/20 Alliance Webinar with CDRH Director Dr. Jeffrey Shuren Announced Read More Analysis and Commentary STEVEN GROSSMAN 10/31/20 Analysis and Commentary STEVEN GROSSMAN 10/31/20 Whether There Is or Whether There Isn't Read More Advocacy at a Glance STEVEN GROSSMAN 10/31/20 Advocacy at a Glance STEVEN GROSSMAN 10/31/20 Pandemic-Related Aid and Delayed Appropriations: to Be Resolved Together in Lame Duck? Read More Analysis and Commentary STEVEN GROSSMAN 10/24/20 Analysis and Commentary STEVEN GROSSMAN 10/24/20 FY 21, FY 22 Appropriations and CDER Priorities Read More Advocacy at a Glance STEVEN GROSSMAN 10/24/20 Advocacy at a Glance STEVEN GROSSMAN 10/24/20 Washington Is Waiting for the Election Read More Analysis and Commentary STEVEN GROSSMAN 10/16/20 Analysis and Commentary STEVEN GROSSMAN 10/16/20 Future Changes in Congressional Committees and the FDA Read More Advocacy at a Glance STEVEN GROSSMAN 10/16/20 Advocacy at a Glance STEVEN GROSSMAN 10/16/20 Congressional Committees Overseeing FDA Will Have Some Changes in the New Congress Read More Analysis and Commentary STEVEN GROSSMAN 10/9/20 Analysis and Commentary STEVEN GROSSMAN 10/9/20 Webinar on Budget, Workload, and Other Priorities for CDER Read More Advocacy at a Glance STEVEN GROSSMAN 10/9/20 Advocacy at a Glance STEVEN GROSSMAN 10/9/20 Life Under the Continuing Resolution Read More Analysis and Commentary STEVEN GROSSMAN 10/1/20 Analysis and Commentary STEVEN GROSSMAN 10/1/20 Understanding the Short-Term CR Read More Advocacy at a Glance STEVEN GROSSMAN 10/2/20 Advocacy at a Glance STEVEN GROSSMAN 10/2/20 FDA to Be Funded under Short-Term Continuing Resolution through December 11 Read More Analysis and Commentary STEVEN GROSSMAN 9/25/20 Analysis and Commentary STEVEN GROSSMAN 9/25/20 How FDA is Funded, ... and Why Read More Advocacy at a Glance STEVEN GROSSMAN 9/25/20 Advocacy at a Glance STEVEN GROSSMAN 9/25/20 FDA Will Begin Fiscal Year 2021 With CR Funding Read More Analysis and Commentary STEVEN GROSSMAN 9/18/20 Analysis and Commentary STEVEN GROSSMAN 9/18/20 Public Trust in the US FDA Read More Newer Posts Older Posts
Analysis and Commentary STEVEN GROSSMAN 12/5/20 Analysis and Commentary STEVEN GROSSMAN 12/5/20 CDRH Update and Future Priorities Read More
Analysis and Commentary STEVEN GROSSMAN 11/19/20 Analysis and Commentary STEVEN GROSSMAN 11/19/20 Time to Give Thanks -- Once Again Read More
Advocacy at a Glance STEVEN GROSSMAN 11/20/20 Advocacy at a Glance STEVEN GROSSMAN 11/20/20 What Happened in 2020? Insights from DC's Top Election Handicapper Read More
Analysis and Commentary STEVEN GROSSMAN 11/12/20 Analysis and Commentary STEVEN GROSSMAN 11/12/20 Where $40 Million Might Go for FY 21 Read More
Advocacy at a Glance STEVEN GROSSMAN 11/13/20 Advocacy at a Glance STEVEN GROSSMAN 11/13/20 Progress on Appropriations; How Much Progress is Unclear Read More
Analysis and Commentary STEVEN GROSSMAN 11/8/20 Analysis and Commentary STEVEN GROSSMAN 11/8/20 What Happens in the Next Few Months? Read More
Advocacy at a Glance STEVEN GROSSMAN 11/8/20 Advocacy at a Glance STEVEN GROSSMAN 11/8/20 Alliance Webinar with CDRH Director Dr. Jeffrey Shuren Announced Read More
Analysis and Commentary STEVEN GROSSMAN 10/31/20 Analysis and Commentary STEVEN GROSSMAN 10/31/20 Whether There Is or Whether There Isn't Read More
Advocacy at a Glance STEVEN GROSSMAN 10/31/20 Advocacy at a Glance STEVEN GROSSMAN 10/31/20 Pandemic-Related Aid and Delayed Appropriations: to Be Resolved Together in Lame Duck? Read More
Analysis and Commentary STEVEN GROSSMAN 10/24/20 Analysis and Commentary STEVEN GROSSMAN 10/24/20 FY 21, FY 22 Appropriations and CDER Priorities Read More
Advocacy at a Glance STEVEN GROSSMAN 10/24/20 Advocacy at a Glance STEVEN GROSSMAN 10/24/20 Washington Is Waiting for the Election Read More
Analysis and Commentary STEVEN GROSSMAN 10/16/20 Analysis and Commentary STEVEN GROSSMAN 10/16/20 Future Changes in Congressional Committees and the FDA Read More
Advocacy at a Glance STEVEN GROSSMAN 10/16/20 Advocacy at a Glance STEVEN GROSSMAN 10/16/20 Congressional Committees Overseeing FDA Will Have Some Changes in the New Congress Read More
Analysis and Commentary STEVEN GROSSMAN 10/9/20 Analysis and Commentary STEVEN GROSSMAN 10/9/20 Webinar on Budget, Workload, and Other Priorities for CDER Read More
Advocacy at a Glance STEVEN GROSSMAN 10/9/20 Advocacy at a Glance STEVEN GROSSMAN 10/9/20 Life Under the Continuing Resolution Read More
Analysis and Commentary STEVEN GROSSMAN 10/1/20 Analysis and Commentary STEVEN GROSSMAN 10/1/20 Understanding the Short-Term CR Read More
Advocacy at a Glance STEVEN GROSSMAN 10/2/20 Advocacy at a Glance STEVEN GROSSMAN 10/2/20 FDA to Be Funded under Short-Term Continuing Resolution through December 11 Read More
Analysis and Commentary STEVEN GROSSMAN 9/25/20 Analysis and Commentary STEVEN GROSSMAN 9/25/20 How FDA is Funded, ... and Why Read More
Advocacy at a Glance STEVEN GROSSMAN 9/25/20 Advocacy at a Glance STEVEN GROSSMAN 9/25/20 FDA Will Begin Fiscal Year 2021 With CR Funding Read More
Analysis and Commentary STEVEN GROSSMAN 9/18/20 Analysis and Commentary STEVEN GROSSMAN 9/18/20 Public Trust in the US FDA Read More
